NOVO.B.DK

433.1

-0.21%↓

COLO.B.DK

602.6

-0.13%↓

GMAB.DK

1,405.5

+3.16%↑

ZEAL.DK

364.5

-1%↓

AMBUB.DK

98

+0.72%↑

NOVO.B.DK

433.1

-0.21%↓

COLO.B.DK

602.6

-0.13%↓

GMAB.DK

1,405.5

+3.16%↑

ZEAL.DK

364.5

-1%↓

AMBUB.DK

98

+0.72%↑

NOVO.B.DK

433.1

-0.21%↓

COLO.B.DK

602.6

-0.13%↓

GMAB.DK

1,405.5

+3.16%↑

ZEAL.DK

364.5

-1%↓

AMBUB.DK

98

+0.72%↑

NOVO.B.DK

433.1

-0.21%↓

COLO.B.DK

602.6

-0.13%↓

GMAB.DK

1,405.5

+3.16%↑

ZEAL.DK

364.5

-1%↓

AMBUB.DK

98

+0.72%↑

NOVO.B.DK

433.1

-0.21%↓

COLO.B.DK

602.6

-0.13%↓

GMAB.DK

1,405.5

+3.16%↑

ZEAL.DK

364.5

-1%↓

AMBUB.DK

98

+0.72%↑

Search

H Lundbeck A-S

Geschlossen

34.34 0.64

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

34.12

Max

34.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

562M

1.2B

Verkäufe

694M

6.2B

KGV

Branchendurchschnitt

10.5

39.857

EPS

1.53

Dividendenrendite

2.61

Gewinnspanne

18.476

Angestellte

5,700

EBITDA

811M

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.61%

2.42%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.6B

34B

Vorheriger Eröffnungskurs

33.7

Vorheriger Schlusskurs

34.34

H Lundbeck A-S Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Juli 2025, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16. Juli 2025, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16. Juli 2025, 23:00 UTC

Akquisitionen, Fusionen, Übernahmen

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16. Juli 2025, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16. Juli 2025, 23:44 UTC

Market Talk

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16. Juli 2025, 23:42 UTC

Market Talk

Nikkei May Fall as Yen Strengthens -- Market Talk

16. Juli 2025, 23:24 UTC

Market Talk

Australian Job Market Data to Shape RBA Calls -- Market Talk

16. Juli 2025, 23:18 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16. Juli 2025, 23:18 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Cuts Top End of 2025 Production Guidance

16. Juli 2025, 23:17 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: Production Recovery Underway in Cooper Basin

16. Juli 2025, 23:17 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16. Juli 2025, 23:17 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: Cooper Basin Production Impacted by Floods in 2Q

16. Juli 2025, 23:16 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16. Juli 2025, 23:16 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16. Juli 2025, 23:13 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16. Juli 2025, 23:13 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16. Juli 2025, 23:12 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16. Juli 2025, 23:12 UTC

Akquisitionen, Fusionen, Übernahmen

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16. Juli 2025, 23:11 UTC

Akquisitionen, Fusionen, Übernahmen

Santos 2Q Free Cash Flow From Operations US$620 Million

16. Juli 2025, 23:11 UTC

Akquisitionen, Fusionen, Übernahmen

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16. Juli 2025, 23:11 UTC

Akquisitionen, Fusionen, Übernahmen

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16. Juli 2025, 23:11 UTC

Akquisitionen, Fusionen, Übernahmen

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16. Juli 2025, 23:11 UTC

Akquisitionen, Fusionen, Übernahmen

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16. Juli 2025, 22:43 UTC

Market Talk

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16. Juli 2025, 22:35 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

16. Juli 2025, 22:35 UTC

Market Talk
Ergebnisse

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16. Juli 2025, 22:33 UTC

Market Talk
Ergebnisse

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16. Juli 2025, 22:28 UTC

Market Talk
Ergebnisse

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16. Juli 2025, 22:22 UTC

Market Talk
Ergebnisse

Market Talk Roundup: Latest on U.S. Politics

16. Juli 2025, 22:22 UTC

Market Talk
Ergebnisse

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Peer-Vergleich

Kursveränderung

H Lundbeck A-S Prognose

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.